Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. - Wikidata - awgldk - TriplyDB

Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.

Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.

http://www.wikidata.org/entity/Q38928592

about

New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions.An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma Reductive carboxylation is a major metabolic pathway in the retinal pigment epithelium.Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin.A Red-Light-Activated Ruthenium-Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells.Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer.From the Cover: Inhibitors of Nicotinamide Phosphoribosyltransferase Cause Retinal Damage in Larval Zebrafish.Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors.Nonproliferative and Proliferative Lesions of the Ratand Mouse Special Sense Organs(Ocular [eye and glands], Olfactory and Otic)Identification of a novel NAMPT inhibitor by combinatorial click chemistry and chemical refinement

P2860

Q26745678-FDB828C3-CB37-4BB7-B376-7118AC7AAEF2 Q28069876-92E62E3D-9B99-41D4-A19C-4EC50CCCC643 Q33422176-9EB4D5B6-92C8-4592-BAF9-B17C90489DC5 Q35407970-CD81B725-3078-4D04-B294-3F3D37F4E788 Q37534085-4B57CBCB-DE97-455E-8B09-750B31E70138 Q37534139-4E78AE88-20CD-4E59-97BC-76332EAB1FBF Q38736710-62B1F7F4-0E1E-4A50-9A3A-75D74A8A4F48 Q39195646-67D92BB5-0795-45C6-A4BC-994EE3E2855F Q41916219-29EE4FB6-DF74-4218-BCCA-8FD354851027 Q47147548-9ACD8BA4-C791-4A2B-836E-4FFC06564102 Q49603956-FAEDD7C3-7D2A-4114-A7AF-18FDA2A88B18 Q55029401-B79C8733-56CA-479A-89E3-2FB50683EA52 Q57644373-1170D9F5-4DF2-4C52-9577-989B209A6378 Q58044476-742DAD07-A5A5-48DC-8738-5BC15D821031

P2860

Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.

http://www.wikidata.org/entity/Q38928592

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Retinal toxicity, in vivo and ...... ide phosphoribosyltransferase.

@en

type

label

Retinal toxicity, in vivo and ...... ide phosphoribosyltransferase.

@en

prefLabel

Retinal toxicity, in vivo and ...... ide phosphoribosyltransferase.

@en

P1433

Q38928592-1AABCAA0-C5F4-47C8-BFC4-5EACC2FD5DB8

P1476

Q38928592-5F648ED4-898D-447F-8FF2-9C466AE18858

P2093

Q38928592-0EFDBF2D-F9CD-49A1-A64D-B820420FA2C0

Q38928592-0FAF2EBA-D308-455B-91B8-25CDA2D98BBB

Q38928592-1938481A-24A2-4E7B-99A6-3AEB829271AE

Q38928592-267CCABB-A891-4AFB-820B-23F444B6F6BC

Q38928592-28F38D17-AA82-4B5A-9B20-B0FE0B0854D2

Q38928592-44A50882-C47D-4194-9BB4-85FC1B325C51

Q38928592-603725FE-4C1E-41F0-BA25-C68A22BFD053

Q38928592-6E696FCB-CB9F-4D6A-BBE9-36BE8020B832

Q38928592-7600FD41-C566-4B17-A200-561AE328A38F

Q38928592-8F54D315-66FF-4642-B98A-EEDB3D4BF35C

P2860

Q38928592-0363604E-88C3-46E6-9561-0820EEEA1E65

Q38928592-14FF08D7-4B17-4094-93A7-CD33D8AD7C2C

Q38928592-2E61D391-BC02-4CFD-BE77-EA967D2B378E

Q38928592-5A76A73A-E670-457E-857B-5B9B3411FA4E

Q38928592-62E97B5E-2226-455B-991D-B49A8754160F

Q38928592-67F71BF0-7409-411C-860B-DC3F7B2A9A58

Q38928592-72FEA61E-0AE5-49CC-9372-B4C3EAAB4961

Q38928592-9031089B-F3F1-410D-A6E0-D3CD1F9F60AC

Q38928592-93ACB98E-A0BB-4CBC-852E-61E7D33DB317

Q38928592-9502939A-BAE7-4A4F-AD7E-AC110FC32C06

P304

Q38928592-F90E4754-77E5-4D7C-BD52-B7E8654C4BEA

P31

Q38928592-B82EB071-5F96-4E1B-AAA9-A275EDA6A7EF

P356

Q38928592-7B3C086A-8394-4A87-AF1E-2D33A74F0608

P433

Q38928592-88F8B69F-8775-4343-833F-3607E1C8526E

P478

Q38928592-7F72C802-0343-4EC2-A43A-A46A5B93C780

P50

Q38928592-3B061007-9558-4FEB-9538-688C3DA914D8

Q38928592-82FA8FC0-C3AA-46BB-BCE1-431F4D62843C

P577

Q38928592-087F6087-88B6-4456-BA3C-1E72EC0C9268

P698

Q38928592-DA1B8970-A0FD-4FE5-855C-F3728D9F8433

P356

P1433

Toxicological Sciences

P1476

Retinal toxicity, in vivo and ...... mide phosphoribosyltransferase

@en

P2093

Bianca M Liederer

http://www.w3.org/2001/XMLSchema#string

Bobbi McCray

http://www.w3.org/2001/XMLSchema#string

Cynthia Farman

http://www.w3.org/2001/XMLSchema#string

Deepak Sampath

http://www.w3.org/2001/XMLSchema#string

Dinah L Misner

http://www.w3.org/2001/XMLSchema#string

Hirdesh Uppal

http://www.w3.org/2001/XMLSchema#string

Jason Oeh

http://www.w3.org/2001/XMLSchema#string

Jatinder Singh

http://www.w3.org/2001/XMLSchema#string

Joseph Beyer

http://www.w3.org/2001/XMLSchema#string

Mara A Kauss

http://www.w3.org/2001/XMLSchema#string

P2860

NMNAT1 mutations cause Leber congenital amaurosis

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase

Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.

Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy

Metabolic reprogramming: a cancer hallmark even warburg did not anticipate

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.

NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences.

P304

163-172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/TOXSCI/KFU268

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

144

http://www.w3.org/2001/XMLSchema#string

P50

Peter S Dragovich

P577

2014-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25505128

http://www.w3.org/2001/XMLSchema#string